My two CentsWell, FINS underperformed my hopes and expectations. I'm dissapointed but I also see some positives. I don't get too excited about % change from Q1 2021 as that was so long ago and this company should be evolving at a rapid pace. What I have done is taken Q1 2022 multiplied it by 4 and compared that to our recent year end 2021 FINS. Here is what I see:
2021 Total Revenue - $49M
Q1 2022 x 4- $42.8M (Odd as the January 11th NR stated Covid testing up %300)
2021 Health Revenue- $45M
Q1 Health Rev x 4- $34.4M (As mentioned above, we can see health/COVID is down not up)
2021 AI Revenue - $4M
Q1 AI Revenue x4- $8.4M (I'm happy to see that AI revenue is increasing)
2021 Net Profit- $9M
Q1 Net Revenue x4- $5.2M (Perhaps the margins on our AI aren't that great)
In summary, Health/COVID revenue is down, AI revenue is up. Hopefully Q2 will tell us a better story. If Datametrex lives up to their end of the deal I would expect the government contracts to incrementaly increase over time. Q2, Q3, and year end will tell a better story there. However, we are still very much a health care company that is dabblin in AI. It is sort of laughable that Marshall refers to us as a core AI business. I hope we get there and that is why I invested but there is much work to be done before that statement can be made.
I don't expect these FINS to have any real effect on our SP. I guess now we wait for the big month of news in April (maybe she meant April 2023), share buy back numbers, and the TSX uplist. I do believe that the uplist will result in a nice little SP boost.
Thoughts comments???? What did I miss?